Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations
NCT ID: NCT02013635
Last Updated: 2016-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
232 participants
OBSERVATIONAL
2011-07-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The onset may be acute (less than 2 days), subacute (between 2 and 30 days) or chronic (more than 30 days). The clinical presentation is highly variable and includes patients with only a mild headache, others with focal neurological deficits and a few with a dramatic syndrome and a coma. Moreover the evolution can be very different with unpredictable outcome: more often it is favorable with a low mortality rate, but in some cases it can be a worse course. The aim of this study is to evaluate the correlation of some biological markers: thrombin generation test and D-Dimers (marker of fibrin generation and degradation) with the type of onset or the wide spectrum of clinical presentations or the different modes of evolution.
All patients over 16 years ago may be included in the program when CVT diagnosis is proved by magnetic resonance angiography (MRA). For each included patient, there are four blood assays: the first just at the time of diagnosis and before the beginning of treatment, the second before the beginning of the oral anticoagulant treatment. The third assay is done in the third month at the time of a MRA. The last assay is made one month after the end of the anticoagulant treatment or in 12th month after the beginning of the disease if the treatment goes on.
For each sample, the investigators perform a thrombin generation test and a D-Dimers measurement.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cerebral Venous Thrombosis
patients over 16 years old with acute cerebral venous thrombosis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LE CAM DUCHEZ VERONIQUE, MD
Role: STUDY_DIRECTOR
CHU HOPITAUX DE ROUEN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Amiens
Amiens, , France
Chu D' Angers
Angers, , France
Ch Victor Dupouy
Argenteuil, , France
CH Côte Basque
Bayonne, , France
Hôpital Jean Minjioz
Besançon, , France
Hôpital Pellegrin - CHU Bordeaux
Bordeaux, , France
Hôpital de la Cavale Blanche
Brest, , France
Hôpital Neurologique de Lyon
Bron, , France
Hôpital Côte de Nacre
Caen, , France
CHU Estaing
Clermont-Ferrand, , France
Hôpitaux Civils de Colmar
Colmar, , France
C.H. de Compiègne
Compiègne, , France
Hôpital Henri Mondor
Créteil, , France
CHU-Hôpital Général
Dijon, , France
C.H.I. Eure-Seine
Évreux, , France
C.H.U. de Grenoble
Grenoble, , France
C.H. de La Rochelle
La Rochelle, , France
C.H. de Versailles
Le Chesnay, , France
Hôpital J. Monod
Le Havre, , France
C.H.U. Limoges
Limoges, , France
C.H. François Quesnay
Mantes-la-Jolie, , France
Hôpital de la Timone
Marseille, , France
C.H. de Meaux
Meaux, , France
Hôpital Guy de Chauliac
Montpellier, , France
Hôpital Nord de Laënnec
Nantes, , France
G.H.U. Carémeau
Nîmes, , France
G.H. Paris Saint-Joseph
Paris, , France
GH Pitié-Salpêtrière
Paris, , France
C.H. de Perpignan - Hôpital Saint-Jean
Perpignan, , France
CHI de Poissy- site de Poissy
Poissy, , France
C.H.U de Poitiers
Poitiers, , France
CHU hopitaux de rouen
Rouen, , France
C.H. Yves Le Foll
Saint-Brieuc, , France
C.H. Saint-Denis
Saint-Denis, , France
C.H.U de Strasbourg
Strasbourg, , France
CHRU Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Triquenot Bagan A, Crassard I, Drouet L, Barbieux-Guillot M, Marlu R, Robinet-Borgomino E, Morange PE, Wolff V, Grunebaum L, Klapczynski F, Andre-Kerneis E, Pico F, Martin-Bastenaire B, Ellie E, Menard F, Rouanet F, Freyburger G, Godeneche G, Allano HA, Moulin T, Mourey G, Derex L, Berruyer M, Runavot G, Trichet C, Viader F, Le Querrec A, Husein TT, Cluet-Dennetiere S, Macian-Montoro F, Donnard M, Guillon B, Ternisien C, Zuber M, Laplanche S, Tassan P, Peeltier JY, Canaple S, Roussel B, Gaillard N, Scavazza E, Le Cam Duchez V. Cerebral Venous Thrombosis: Clinical, Radiological, Biological, and Etiological Characteristics of a French Prospective Cohort (FPCCVT)-Comparison With ISCVT Cohort. Front Neurol. 2021 Nov 8;12:753110. doi: 10.3389/fneur.2021.753110. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010/087/HP
Identifier Type: -
Identifier Source: org_study_id